ERYTECH Announces Withdrawal of its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission

ERYTECH today announced its decision to withdraw the current MAA for GRASPA for the treatment of acute lymphoblastic leukemia (ALL). The Company determined that the time allowed in the CHMP procedure was not sufficient to provide the additional data requested in the CHMP’s Day 180 List of Outstanding Issues (LOI). The Company intends to resubmit an MAA around mid-2017.

Menu